Houlihan Lokey combines middle-market advisory leadership, sponsor-driven M&A upside, and counter-cyclical restructuring; the report’s probability-weighted five-year target is $237.93 from $142.84.
Houlihan Lokey, Inc. (NYSE: HLI) is a premier global independent investment bank that delivers specialized financial advisory services spanning mergers and acquisitions (M&A), capital markets, corporate restructuring, and financial valuation advisory [cite: 1, 2, 3]. The company operates primarily within the global middle market—generally defined as transactions with enterprise values below $1 billion—where it maintains a dominant market position by transaction volume [cite: 2]. Houlihan Lokey organizes its operations into three distinct, complementary business segments: Corporate Finance (CF), Financial Restructuring (FR), and Financial and Valuation Advisory (FVA) [cite: 1, 4, 5].
+---------------------------------------+
| Houlihan Lokey Inc. |
| (NYSE: HLI) |
+-------------------+-------------------+
|
+-----------------------------------------+-----------------------------------------+
| | |
v v v
+-----------------------+ +-----------------------+ +-----------------------+
| Corporate Finance | | Financial Restructuring| | Financial & Valuation |
| (~65-70%) | | (~17-20%) | | Advisory (~13-15%) |
+-----------+-----------+ +-----------+-----------+ +-----------+-----------+
| | |
v v v
Sell-Side & Buy-Side M&A Out-of-Court Restructuring Fairness Opinions & Valuation
Capital Markets Advisory Chapter 11 Reorganization Portfolio Valuation (Illiquid)
Private Credit Placement Distressed M&A & Liability Mgmt Solvency & Tax Opinions
The firm generates revenue through fee-for-service arrangements across its three business units [cite: 3]. Corporate Finance earns success-based transaction fees upon the closing of M&A advisory mandates and private capital placements [cite: 4, 5]. Financial Restructuring generates monthly retainer fees supplemented by milestone success fees upon the execution of complex debt reorganizations, Chapter 11 proceedings, and out-of-court debt workouts [cite: 2, 4, 6]. Financial and Valuation Advisory derives revenue from fixed or hourly fees by rendering independent valuation opinions, portfolio valuations for private asset managers, and board-level fairness opinions [cite: 2, 4, 5, 7]. Geographically, while the United States generates the clear majority of total advisory revenue, the firm actively expands its footprint across Europe, the Middle East, and the Asia-Pacific region [cite: 7, 8].
| Business Segment | Revenue Contribution (LTM) | Key Products & Services | Core Customer Segments | Primary End Markets |
|---|---|---|---|---|
| Corporate Finance (CF) | ~65% – 70% | Sell-side/buy-side M&A advisory, private capital placement, capital markets advisory | Middle-market corporations, private equity sponsors, growth enterprises | Technology, Business Services, Industrials, Healthcare, Financials, Consumer |
| Financial Restructuring (FR) | ~17% – 20% | Out-of-court workouts, Chapter 11 reorganizations, liability management, distressed M&A | Corporate debtors, ad hoc creditor committees, distressed PE sponsors, institutional lenders | Leveraged corporate borrowers, stressed middle-market companies |
| Financial & Valuation Advisory (FVA) | ~13% – 15% | Fairness & solvency opinions, illiquid portfolio valuation, financial reporting compliance | Corporate boards of directors, private credit funds, hedge funds, asset managers | Institutional asset managers, alternative investment funds |
Corporate clients and private equity sponsors choose Houlihan Lokey over bulge-bracket investment banks and boutique competitors due to its deep sector-specific expertise, extensive private equity sponsor coverage network, and leadership in fairness opinions and restructuring mandates [cite: 2, 7]. Furthermore, Houlihan Lokey's operational structure features a counter-cyclical design: when corporate M&A velocity decelerates during economic downturns, restructuring mandates expand, creating a built-in revenue hedge across credit cycles [cite: 1, 2, 3].
Houlihan Lokey’s financial performance is driven by four key operational metrics: Managing Director (MD) headcount, MD productivity (revenue generated per MD), transaction closure volume, and average advisory fee size [cite: 4, 5, 9]. Strategic expansion focuses on organic hiring of senior talent, bolt-on acquisitions of specialized advisory boutiques, global geographic expansion, and the build-out of its private credit and Capital Solutions platforms [cite: 1, 9, 10].
In Corporate Finance, the firm advises middle-market business owners and financial sponsors on sell-side transactions, buy-side acquisitions, capital raises, and debt placements [cite: 4, 5, 7]. Advisory engagements typically involve identifying acquirers or capital sources, structuring transaction terms, and negotiating closing agreements [cite: 4, 5, 7].
Financial Restructuring mandates require advising either corporate debtors or creditor constituencies (such as ad hoc bondholder groups, lender syndicates, and private credit providers) in overleveraged situations [cite: 2, 5, 6]. Services include restructuring balance sheet debt, negotiating debt-to-equity conversions, executing distressed asset sales, and arranging dip-financing or exit financing [cite: 2, 5, 6].
Financial and Valuation Advisory provides independent technical valuations of business entities, complex financial instruments, and illiquid alternative investment portfolios [cite: 2, 4, 7]. Its fairness and solvency opinion practice delivers third-party valuation assessments to corporate boards evaluating fiduciary responsibilities in M&A transactions [cite: 2, 7].
Houlihan Lokey’s economic moat relies on network effects, proprietary institutional knowledge, brand reputation, and high client switching costs [cite: 2, 7].
+---------------------------------------------------------------------------------------------------+
| HOULIHAN LOKEY COMPETITIVE MOAT |
+---------------------------------------------------------------------------------------------------+
| 1. SPONSOR ECOSYSTEM NETWORK EFFECTS |
| - Covers 1,900+ Private Equity and Credit Funds via 30 senior dedicated officers. |
| - Propelled by proprietary database tracking buyer behaviors across 850+ PE sales over 5 years. |
| |
| 2. COUNTER-CYCLICAL PLATFORM HEDGE |
| - Restructuring expansion offsets Corporate Finance M&A contractions during credit cycles. |
| |
| 3. REPUTATION & SWITCHING COSTS |
| - #1 Global Fairness Opinion provider over 25 years (1,170 deals); critical for board risk. |
+---------------------------------------------------------------------------------------------------+
The firm maintains dedicated institutional coverage of over 1,900 private equity funds, venture capital firms, family offices, and alternative credit managers globally [cite: 7]. Having advised on the sale of over 850 companies to financial sponsors over the past five years, the firm retains a comprehensive database of buyer preferences, valuation metrics, and transaction behaviors [cite: 7]. This network effect creates a self-reinforcing flywheel: extensive sponsor relationships grant superior market intelligence, attracting more middle-market sell-side mandates, which further solidifies relationships with private capital providers [cite: 7].
The brand functions as a primary asset in financial opinion rendering and debt restructurings [cite: 2, 7]. Houlihan Lokey has completed 1,170 fairness opinions over the past 25 years, ranking first globally [cite: 2]. Corporate boards facing potential shareholder litigation rely on this brand equity to satisfy fiduciary obligations [cite: 2]. In financial restructuring, where legal and financial workouts are complex, debt holders and debtors turn to established advisors, generating high client retention and switching costs during active mandates [cite: 2, 6].
The global middle-market advisory sector remains broad and highly fragmented [cite: 2]. For calendar year 2025, market data recorded 41,914 global mid-cap transactions under $1 billion in deal value [cite: 2]. Houlihan Lokey’s lead in deal count represents approximately a 2% global market share in this mid-cap space, leaving substantial headroom for organic market share gains [cite: 2].
Private equity dry powder in the United States stands at approximately $650 billion [cite: 7]. As private equity funds manage aged portfolio company inventories, the requirement to exit investments and return capital to limited partners provides a long-term catalyst for middle-market sell-side M&A advisory services [cite: 7].
Total Global Mid-Cap Transactions (<$1B Value): 41,914 Deals
[====================================================================================================] 100%
[==] Houlihan Lokey Market Share: ~2% (Room for Significant Long-Term Market Expansion)
| Banking Category | Primary Competitors | Houlihan Lokey Competitive Positioning | Market Share Trend |
|---|---|---|---|
| Independent Boutiques | Evercore, Moelis & Co, Lazard, PJT Partners, Perella Weinberg | Dominates overall deal volume and mid-market mandates; less reliant on volatile mega-cap M&A than Evercore/Moelis [cite: 2, 6, 11]. | Gaining Share in mid-cap corporate finance and restructuring [cite: 2]. |
| Middle-Market Specialists | Jefferies, Piper Sandler, Stifel, William Blair, Baird, Harris Williams | Broader sector coverage, superior international footprint, and larger financial sponsor database [cite: 2, 6, 7]. | Holding / Gaining Share across key sector verticals [cite: 2, 6]. |
| Bulge-Bracket Investment Banks | Goldman Sachs, JPMorgan Chase, Morgan Stanley | Focuses on mid-cap deals ($100M–$500M) often under-serviced by bulge-bracket banks pursuing mega-cap fees [cite: 2, 9]. | Gaining Share in private equity sell-side execution [cite: 2, 7]. |
Houlihan Lokey reported financial results for the second quarter of fiscal 2027 (quarter ended September 30, 2026) on October 28, 2026 [cite: 1, 4, 12]. Total revenues reached $692 million, up 4.8% year-over-year compared to $660 million in Q2 FY2026 [cite: 4, 5].
Fiscal Q2 2027 Financial Highlights (Quarter Ended Sept 30, 2026):
• Revenue: $692M (+5% YoY) vs. Consensus $627.39M (BEAT by +10.3%)
• Adjusted EPS: $1.85 (+1% YoY) vs. Consensus $1.63 (BEAT by +13.5%)
• GAAP Diluted EPS: $1.64 vs. $1.63 YoY
• Unrestricted Cash & Investment Securities: $888M
Quarterly performance exceeded Wall Street analyst expectations on top and bottom lines [cite: 13]. Revenue of $692 million beat the consensus estimate of $627.39 million by $64.61 million (a 10.3% positive surprise) [cite: 13]. Adjusted diluted EPS of $1.85 beat the Wall Street consensus estimate of $1.63 by $0.22 per share (a 13.5% positive surprise) [cite: 13]. GAAP diluted EPS grew modestly to $1.64 from $1.63 in the prior-year period [cite: 4].
| Metric | Fiscal Q2 2027 | Fiscal Q2 2026 | YoY Change | Wall Street Consensus | Surprise (%) |
|---|---|---|---|---|---|
| Revenues | $692 million | $660 million | +4.8% | $627.39 million | +10.3% Beat [cite: 13] |
| Operating Income | $154 million | $151 million | +2.0% | N/A | N/A |
| Operating Margin | 22.3% | 22.9% | -60 bps | N/A | N/A |
| Net Income (GAAP) | $109 million | $111 million | -1.8% | N/A | N/A |
| Diluted EPS (GAAP) | $1.64 | $1.63 | +0.6% | N/A | N/A |
| Adjusted Net Income | $124 million | $127 million | -2.4% | N/A | N/A |
| Adjusted Diluted EPS | $1.85 | $1.84 | +0.5% | $1.63 | +13.5% Beat [cite: 13] |
Segment performance demonstrated operational divergence:
* Corporate Finance: Revenue grew 9.6% year-over-year to $481 million [cite: 4, 5]. Closed deal volume fell to 142 from 171 in Q2 FY2026, but average fee sizes grew significantly due to deal mix and larger transaction values [cite: 4, 5, 9, 13].
* Financial Restructuring: Revenue decreased 11.9% year-over-year to $118 million as closed transactions declined to 27 from 37, driven primarily by transaction closing schedules [cite: 4, 5, 13].
* Financial and Valuation Advisory: Revenue grew 6.9% year-over-year to $93 million across 1,071 fee events, supported by steady expansion in recurring portfolio valuation services for alternative asset managers [cite: 2, 4, 5, 13].
| Segment | Q2 FY27 Revenue | Q2 FY26 Revenue | YoY Change | Q2 FY27 Metric | Q2 FY26 Metric |
|---|---|---|---|---|---|
| Corporate Finance | $481 million | $439 million | +9.6% | 142 Closed Deals | 171 Closed Deals [cite: 4, 5] |
| Financial Restructuring | $118 million | $134 million | -11.9% | 27 Closed Deals | 37 Closed Deals [cite: 4, 5] |
| Financial & Valuation Advisory | $93 million | $87 million | +6.9% | 1,071 Fee Events | 1,075 Fee Events [cite: 4, 5] |
Management maintained its full-year fiscal 2027 guidance targets: an adjusted compensation expense ratio of 61.5% and an adjusted effective tax rate between 26.0% and 28.0% [cite: 1, 13]. During the earnings call, leadership highlighted expectations for an unseasonably strong second half of fiscal 2027, citing recovering M&A pipelines and a rebuilding restructuring backlog in technology and software sectors expected to materialize across calendar 2027 and 2028 [cite: 1, 9].
Following the release, the stock rose 3.8% in regular trading to close at $137.38, before dipping 3.55% in after-hours trading as market participants noted a 10.8% increase in adjusted non-compensation expenses ($91 million) [cite: 2, 4, 13]. Equity analysts at major Wall Street firms (including JPMorgan and KBW) subsequently reiterated positive ratings, maintaining target prices near $160–$162 [cite: 14, 15]. By mid-November 2026, the stock traded at $142.84 [cite: 15, 16].
Houlihan Lokey’s financial structure relies on a asset-light model with high return on equity (ROE of 17.3%–18.0%), low capital expenditure requirements, and cash conversion efficiency [cite: 13, 15, 16]. The balance sheet maintains debt-light liquidity, holding $888 million in cash, cash equivalents, and investment securities, with net cash of $343 million ($4.94 per share) [cite: 4, 5, 15].
| Valuation Metric | Current Value (Nov 2026) | Historical 5-Yr Average | Sector Peer Median |
|---|---|---|---|
| Share Price | $142.84 | N/A | N/A [cite: 15, 16] |
| Market Capitalization | $9.92 Billion | N/A | N/A [cite: 15, 16] |
| Enterprise Value (EV) | $9.57 Billion | N/A | N/A [cite: 15] |
| Trailing P/E Ratio (GAAP) | 23.95x | 23.83x | 14.90x [cite: 15, 16, 17] |
| Forward P/E Ratio | 17.57x | 19.50x | 14.20x [cite: 15, 16] |
| Price / Sales (P/S) | 3.88x | 3.50x | 1.80x [cite: 15] |
| Price / Book (P/B) | 4.30x | 4.10x | 2.50x [cite: 15, 16] |
| Dividend Yield | 1.96% ($2.80/share) | 1.85% | 2.50% [cite: 15, 16] |
The firm has historically compounded revenues at an 11% to 16% 5-year CAGR, driven by MD recruitment, market share expansion, and acquisitions [cite: 7, 18]. Valuation multiples reflect a premium over traditional investment banks due to lower revenue volatility provided by its counter-cyclical restructuring platform and strong ROIC (14.8%) [cite: 1, 2, 15].
+---------------------------------------------------------------------------------------------------+
| HOULIHAN LOKEY RISK MATRIX SUMMARY |
+---------------------------------------------------------------------------------------------------+
| HIGH IMPACT |
| - Macro Cyclicality & Sponsor Freeze (M&A deal delays) |
| - Talent Poaching & Compensation Pressure (Margin erosion) |
| |
| MEDIUM IMPACT |
| - M&A Integration Risk (Boutique integration delays) |
| - Regulatory Oversight (Fairness opinion & antitrust litigation risks) |
| |
| LOW IMPACT / MANAGED |
| - Balance Sheet Liquidity Risk (Mitigated by $343M Net Cash position) |
+---------------------------------------------------------------------------------------------------+
| Vulnerability Level | Event Scenario (What Could Go Wrong) | Early Warning Indicators | Impact on Long-Term Investment Thesis |
|---|---|---|---|
| Primary Thesis Threat | Sustained freeze across M&A and corporate debt restructurings simultaneously (credit market freeze). | Pitch volume contractions across quarters; MD productivity falling below $6.5M; PE dry powder remaining deployment-constrained. | Severe: Disrupts earnings growth, compresses P/E multiples toward peer medians (14x–16x), and limits top-line expansion. |
| Operational Warning Sign | Persistent expansion in compensation expense ratio beyond the target 61.5%. | Consecutive quarterly reports with compensation ratios above 63.5% alongside non-comp cost expansion. | Moderate: Erodes net margins from 16.5% toward 13%–14%, dampening EPS growth and free cash conversion. |
| Transient Cyclical Risk | Intermittent quarterly closing delays across Corporate Finance or Financial Restructuring mandates. | Quarterly divergence between completed deal counts and pipeline mandates, without structural loss of MD talent. | Low: Short-term earnings volatility creates valuation dislocations without altering multi-year compounding potential. |
To evaluate Houlihan Lokey’s five-year financial trajectory (FY2026 to FY2031), a multi-scenario model was constructed using the baseline inputs:
* Current Share Price: $142.84 [cite: 15, 16, 20]
* Baseline FY2026 Revenue: $2,618.0 Million ($2.618 Billion) [cite: 1, 2, 20]
* Baseline Diluted Share Count: 69.42 Million [cite: 15, 20]
* Baseline Annual Dividend: $2.80 per share [cite: 15, 20]
5-YEAR PRICE TARGET TRAJECTORY (BASE CASE)
Year 0 (FY26 Baseline): $142.84
Year 1 (FY27 Projection): $156.40
Year 2 (FY28 Projection): $171.20
Year 3 (FY29 Projection): $187.50
Year 4 (FY30 Projection): $205.30
Year 5 (FY31 Implied Target): $226.97 (Total Return with Dividends: +71.3%, Annualized: 11.4%)
| Scenario | Baseline (FY26) | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 Target (USD) | Cumulative Dividends | Total Year 5 Value |
|---|---|---|---|---|---|---|---|---|
| Low Case | $142.84 | $130.50 | $124.20 | $118.60 | $114.10 | $110.55 | $15.14 | $125.69 [cite: 20] |
| Base Case | $142.84 | $156.40 | $171.20 | $187.50 | $205.30 | $226.97 | $17.55 | $244.52 [cite: 20] |
| High Case | $142.84 | $178.20 | $221.40 | $272.90 | $332.80 | $398.16 | $20.60 | $418.76 [cite: 20] |
| Scenario | Revenue Metric in Year 5 | Margin / EPS Assumption | Valuation Multiple | Current Share Price (USD) | Implied Future Share Price (USD) | 5-Year Total Return (%) | Annualized Return (%) | Probability Weight |
|---|---|---|---|---|---|---|---|---|
| Low Case | $3,341.3M | 14.0% Net Margin / $6.91 EPS | 16.0x P/E | $142.84 | $110.55 | -11.9% | -2.5% | 20% [cite: 20] |
| Base Case | $4,216.3M | 16.5% Net Margin / $10.81 EPS | 21.0x P/E | $142.84 | $226.97 | +71.3% | +11.4% | 60% [cite: 20] |
| High Case | $5,265.7M | 18.5% Net Margin / $15.93 EPS | 25.0x P/E | $142.84 | $398.16 | +192.7% | +24.0% | 20% [cite: 20] |
| Probability-Weighted Target | $4,251.2M | $10.74 Weighted EPS | 20.8x P/E | $142.84 | $237.93 | +78.9% | +12.3% | 100% [cite: 20] |
COMPOUNDING ADVISORY LEADER
| Scorecard Metric | Score (1–10) | Narrative Assessment |
|---|---|---|
| Management Alignment | 8.0 / 10 | Insider ownership stands at 4.97%, executive team tenure averages over 25 years, and compensation aligns with shareholder metrics [cite: 1, 2, 15]. |
| Revenue Quality | 8.5 / 10 | High-margin, capital-light fee streams; counter-cyclical restructuring balances corporate finance volatility [cite: 1, 2, 3]. |
| Market Position | 9.5 / 10 | Holds #1 rankings globally in M&A deal count, debt restructurings, and fairness opinions [cite: 2]. |
| Growth Outlook | 8.0 / 10 | Supported by $650B+ in PE dry powder, software restructuring maturity walls, and international expansion [cite: 1, 7, 9]. |
| Financial Health | 9.0 / 10 | Strong liquidity with $888M in cash/investments, net cash of $343M ($4.94/share), and low financial debt [cite: 4, 5, 15]. |
| Business Viability | 9.0 / 10 | Durable business model built on relationships with 1,900+ PE sponsors and high switching costs in legal/financial restructurings [cite: 2, 6, 7]. |
| Capital Allocation | 8.5 / 10 | Disciplined track record of 11 consecutive years of dividend growth, opportunistically paired with share repurchases and boutique M&A [cite: 4, 9, 13, 15]. |
| Analyst Sentiment | 7.5 / 10 | Consensus Moderate Buy rating with average price targets near $160–$162, balanced by non-compensation cost monitoring [cite: 13, 14, 15]. |
| Profitability | 8.5 / 10 | Industry-leading operational metrics featuring 94% gross margin, 22.8% operating margin, and 17.3%–18.0% return on equity [cite: 13, 15, 16]. |
| Track Record | 9.0 / 10 | Demonstrated 5-year revenue compounding CAGR of 11%–16% across economic cycles [cite: 7, 18]. |
| OVERALL BLENDED SCORE | 8.6 / 10 | Asset-light financial advisory franchise with durable market share and capital discipline [cite: 2, 15]. |
HIGH-QUALITY FRANCHISE
Houlihan Lokey operates a capital-light investment banking model characterized by middle-market leadership, extensive financial sponsor coverage, and counter-cyclical earnings protection [cite: 1, 2, 3, 7].
+-----------------------------------+
| HOULIHAN LOKEY THESIS DRIVERS |
+-----------------+-----------------+
|
+------------------------------------------+------------------------------------------+
| | |
v v v
+-----------------------------+ +-----------------------------+ +-----------------------------+
| PE DRY POWDER UNLOCK | | RESTRUCTURING TAILWIND | | CAPITAL-LIGHT REINVESTMENT |
| $650B U.S. dry powder will | | Software debt maturities | | High ROE (17.3%) & net |
| drive mid-market M&A exits | | fuel counter-cyclical growth| | cash allow capital returns |
+-----------------------------+ +-----------------------------+ +-----------------------------+
The fundamental thesis rests on three strategic pillars:
* Private Equity Monetization Cycle: Coverage of over 1,900 private equity firms positions Houlihan Lokey to capture fee volume as $650 billion in U.S. PE dry powder is deployed and aged portfolio holdings are monetized [cite: 7].
* Counter-Cyclical Restructuring Support: Looming corporate debt maturities in 2027 and 2028 generate debt restructuring mandates that offset potential slowdowns in classic M&A advisory [cite: 1, 9].
* Capital Discipline & Free Cash Flow: Generating an 17.3% return on equity with $343 million in net cash, the firm retains capital flexibility to fund dividends, buybacks, and boutique advisory acquisitions [cite: 4, 9, 13, 15].
Primary risk factors include non-compensation expense growth, talent retention dynamics, and potential macroeconomic disruptions to deal execution timelines [cite: 4, 9, 10]. The company's underlying fundamentals support a probability-weighted 5-year target price of $237.93 [cite: 20].
BALANCED DUAL ENGINE
Houlihan Lokey's stock currently trades at $142.84, consolidating near its 200-day simple moving average ($142.71) and holding above its 50-day moving average ($134.20) [cite: 15, 21].
Price Action Snapshot (Nov 2026):
• Current Price: $142.84
• 50-Day DMA: $134.20 (Bullish Support Below)
• 200-Day DMA: $142.71 (Consolidating at Major Moving Average)
• 14-Day RSI: 55.22 (Neutral Momentum)
The 10-day moving average crossed above the 50-day moving average in late October 2026, while the 14-day RSI remains neutral at 55.22 [cite: 3, 15, 22]. Following its fiscal Q2 2027 earnings beat, stock price consolidation was tempered by senior Managing Director recruitment and expectations of an unseasonably strong second half of fiscal 2027 [cite: 1, 13, 14]. Technical indicators suggest short-term range-bound trading around the 200-day moving average before testing analyst target price levels near $160.00–$162.00 [cite: 14, 15].
NEUTRAL REGIME CONSOLIDATION
View Houlihan Lokey, Inc. (HLI) stock page
Loading the interactive version of this report…